A5079154981- Renal cell carcinoma treatment
- Renal and related cancers
- Palliative Care and End-of-Life Issues
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Central Venous Catheters and Hemodialysis
- Metastasis and carcinoma case studies
- Prostate Cancer Treatment and Research
- Pain Management and Opioid Use
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Religion, Spirituality, and Psychology
- Gastric Cancer Management and Outcomes
- Grief, Bereavement, and Mental Health
- Patient Dignity and Privacy
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Acute Kidney Injury Research
- Dialysis and Renal Disease Management
- Multiple and Secondary Primary Cancers
- Childhood Cancer Survivors' Quality of Life
- Vascular Tumors and Angiosarcomas
- Cancer, Stress, Anesthesia, and Immune Response
- Ovarian cancer diagnosis and treatment
Hanyang University Seoul Hospital
2023-2025
Pusan National University Yangsan Hospital
2016-2024
Medical Research Institute
2021
Hanil General Hospital
2019
University of Ulsan
2012-2017
Asan Medical Center
2012-2017
Ulsan College
2012-2017
Pusan National University
2017
Creative Research Enterprises (United States)
2017
Korea Electric Power Corporation (South Korea)
2013-2016
Abstract Objective Spirituality is what gives people meaning and purpose in life, it has been recognized as a critical factor patients’ well-being, particularly at the ends of their lives. Studies have demonstrated relationships between spirituality patient-reported outcomes such quality life mental health. Although number studies suggested that spiritual belief can be associated with mortality, results are inconsistent. We aimed to determine whether was related survival advanced cancer...
Purpose To assess the efficacy and safety of first-line modified FOLFIRINOX in patients with advanced urachal cancer. Materials Methods The ULTIMA trial (NCT04611724) is a single-arm, open-label, multicenter phase II study evaluating (Oxaliplatin 85 mg/m2 over 2 hours, Irinotecan 150 1.5 Leucovorin 400 5-FU 2400 46 hours) plus prophylactic pegteograstim recurrent or metastatic cancer every weeks for up to 12 cycles, until disease progression unacceptable toxicity. primary endpoint was...
TPS276 Background: The doublet regimen, which adds docetaxel or androgen receptor-targeted agent (ARTA) such as abiraterone, enzalutamide, apalutamide to deprivation therapy (ADT) has been a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC). A triplet adding abiraterone darolutamide ADT and docetaxel, also demonstrated efficacy. However, while the benefit mHSPC established regimen (ADT + docetaxel), efficacy ARTA not confirmed. Notably, addition shown primarily...
547 Background: Immune checkpoint inhibitors (ICIs) have significantly advanced the treatment of renal cell carcinoma (aRCC). However, many patients develop disease progression, underscoring need for effective second-line therapies. The optimal sequencing after ICI-based remains under investigation. This phase II study evaluates efficacy and safety cabozantinib in with aRCC who progressed on first-line ICI combination Methods: multicenter, prospective, trial enrolled RCC had receiving either...
This study aimed to explore the practices, perceptions, and barriers related specialty palliative care (SPC) referrals among oncologists in Korea, highlighting clinical implications of early integration. A cross-sectional online survey targeting board-certified hemato-oncology specialists was conducted between August 1-25, 2024. The assessed referral attitudes toward SPC integration, criteria, barriers, institutional characteristics. total 227 participated (response rate: 36.7%). Among them,...
<b><i>Background:</i></b> This study investigated the efficacy and toxicity of sorafenib sunitinib as primary treatment for patients with metastatic renal cell carcinoma (mRCC). <b><i>Methods:</i></b> We identified 49 220 treated sunitinib, respectively, first-line therapy in Asan Medical Centre from April 2005 to March 2011. <b><i>Results:</i></b> Disease control rates 71 74% were achieved respectively (p = 0.687)....
The aim of this study was to evaluate the value positron emission tomography/computed tomography (PET/CT) for preoperative staging gastric cancer and compare diagnostic performance PET/CT with that contrast-enhanced computed (CECT).We retrospectively reviewed 74 patients who underwent CECT, subsequent curative surgical resection between April 2007 July 2011. Preoperative CECT images primary tumors stomach lymph node metastases were retrospectively. final diagnoses LN based on...
The purpose of this study was to evaluate clinical characteristics and treatment pattern ovarian clear cell carcinoma (OCCC) in Korea the role adjuvant chemotherapy early stage.Medical records 308 cases from 21 institutions were reviewed data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, death collected.Regarding stage OCCC, it I 194 (63.6%), II 34 (11.1%), III 66 (21.6%), IV 11 (3.6%) patients. All patients underwent...
The aim of this study was to evaluate the value positron emission tomography/computed tomography (PET/CT) for preoperative staging gastric cancer and compare diagnostic performance PET/CT with that contrast-enhanced computed (CECT).We retrospectively reviewed 74 patients who underwent CECT, subsequent curative surgical resection between April 2007 July 2011. Preoperative CECT images primary tumors stomach lymph node metastases were retrospectively. final diagnoses LN based on...
It remains unclear whether capecitabine combined with cisplatin would show similar effects compared standard therapy using gemcitabine and in advanced biliary tract cancer (BTC).Patients BTC who were treated first-line chemotherapy at Asan Medical Center retrospectively analyzed. All patients received either followed by on days 1 8 every 3 weeks (GP group), or 1-14 day (XP group).Of the 134 met inclusion criteria, 78 XP 56 GP. After a median follow-up of 26.2 months, progression-free...
ABSTRACT Objective: The Korean advance directive (K–AD) comprises a value statement, treatment directives, preferences for cardiopulmonary resuscitation (CPR), artificial ventilation, tube feeding, and hospice care, as well proxy appointment. K–AD can facilitate patient's decision making with respect to end-of-life (EoL) care. present study aimed examine the extent which patient–caregiver dyads would use agree on EoL care decisions. Methods: Using descriptive design, 81 cancer patients were...
11512 Background: Angiosarcomas are very rare tumors of vascular or lymphatic origin characterized by a clinical heterogeneity in terms presentation and behavior. It can occur any site body but most commonly originate the skin head neck breast area. Many patients could not receive surgical resection due to its location and/or rapid progression, even who had localized disease. Moreover, conventional cytotoxic chemotherapy has shown limited effect angiosarcoma. Here, we conduct prospective,...
Conclusions: p16 immunohistochemistry (IHC) status correlated with less exposure to smoking and/or alcohol in Korean patients locally advanced tonsillar squamous cell carcinoma (TSCC), and was an independent prognostic factor for survival. Objective: TSCC is more likely be human papillomavirus (HPV)-positive than other head neck (HNSCC) subtypes. The objective of this study ascertain the HPV determine its relationship clinical parameters prognosis. Methods: TSCCs 79 who were treated between...
The purpose of this study was to investigate whether routine insertion peripherally inserted central catheter (PICC) at admission a hospice-palliative care (HPC) unit is acceptable in terms safety and efficacy it results superior patient satisfaction compared usual intravenous (IV) access.Terminally ill cancer patients were randomly assigned two arms: PICC access IV arm. primary endpoint maintenance success rate, defined as the rate functional until intended time (discharge, transfer, or...
Patients with colorectal cancer (CRC) treated curative intent surgery undergo continuous fluorouracil (5-FU) infusion-based chemotherapy using totally implantable central venous port system (TICVPS) in cases high risk of recurrence. Approximately 30% patients relapse after therapy completion, especially within 2 years. Hence, many CRC keep the TICVPS for 6 to 24 months treatment regular intervals flushing. However, little is known about proper interval duration port. The aim this study...
Evidence in favor of adding docetaxel treatment metastatic hormone-sensitive prostate cancer (mHSPC) has led to conjunction with androgen deprivation therapy (ADT) as standard therapy. The aim this study was examine the effectiveness ADT for Korean patients mHSPC real-world practice.A retrospective cohort performed at six hospitals treated plus ADT. Patients were every 3 weeks up cycles 75 mg/m² docetaxel. primary endpoint time castration resistant (CRPC).This included 46 eligible from June...
To investigated the incidence and risk factors of venous thromboembolism (VTE) in patients with advanced gastric cancer (AGC) receiving chemotherapy.All consecutive chemotherapy-naïve AGC who would receive palliative chemotherapy between November 2009 April 2012 our hospital were recruited. Their pretreatment clinical laboratory variables, including D-dimer, recorded. The frequency VTE development survival rates during each cycle regularly thereafter assessed.A total 241 enrolled analyzed....
621 Background: Four-to-six cycles ofplatinum-based CTx have been a standard treatment for aUC. However, disease progresses within several months after completion of 1L CTx. Switch maintenance with effective and safe regimen is an attractive approach to delay progression. PEM showed modest response as salvage in aUC mild toxicities, which are good candidate therapy. We evaluated switch therapy versus OBS pts whose had not progressed. Methods: Eligible without progression 4-6 either cisplatin...
This study aims to assess cell-free DNA (CFD) by a fluorescence assay as biomarker for early prediction of pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients clinical stage II or III TNBC scheduled chemotherapy were prospectively enrolled. All underwent four cycles Adriamycin plus cyclophosphamide (AC), followed cisplatin docetaxel surgery. Blood samples obtained before the initial (baseline-CFD)...